Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BrightPath Biotherapeutics Co's Revenue for the
six
months ended in Mar. 2026 was 円0.05 Mil. BrightPath Biotherapeutics Co's average Accounts Receivable for the
six
months ended in Mar. 2026 was 円0.06 Mil.
Hence, BrightPath Biotherapeutics Co's Receivables Turnover for the
six
months ended in Mar. 2026 was 0.93.
BrightPath Biotherapeutics Co (TSE:4594) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BrightPath Biotherapeutics Co Receivables Turnover Related Terms
BrightPath Biotherapeutics Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co Receivables Turnover Chart
TSE:4594 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Receivables Turnover of 0.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BrightPath Biotherapeutics Co and its competitors. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #826 out of 842 companies in the Biotechnology industry, placing it in the top 98.1%.
Is BrightPath Biotherapeutics Co's Receivables Turnover too high?
BrightPath Biotherapeutics Co's current Receivables Turnover is 0.93. The Biotechnology industry median Receivables Turnover is 5.29. BrightPath Biotherapeutics Co's value of 0.93 is 82.4% below this industry median. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #826 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #826 out of 842 companies for Receivables Turnover. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median Receivables Turnover is 5.29. BrightPath Biotherapeutics Co's value of 0.93 is 82.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrightPath Biotherapeutics Co's current Receivables Turnover of 0.93 is 82.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current Receivables Turnover is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.58, compared to a current price of 円51.00 — trading 1013.5% above its estimated fair value. The current Receivables Turnover is 0.93 and 82.4% below the Biotechnology industry median of 5.29. BrightPath Biotherapeutics Co's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円51.00 is trading 1013.5% above its estimated GF Value™ of 円4.58.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
Receivables Turnover: 0.93
GF Value™: 円4.58 vs. price of 円51.00 (1013.5% above fair value)
Industry Position: 82.4% below the Biotechnology median (#826 of 842)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
47GF Score
Get the complete analysis for TSE:4594
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
